Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton (opens in new tab)
Alkermes plc Buy case: Avadel acquisition adds LUMRYZ sales momentum; alixorexton Phase 2/3 data supports growth. Click for this ALKS stock update.
Read the original article